ClinConnect ClinConnect Logo
Search / Trial NCT00217035

Glutamine Enriched Total Parenteral Feeding and Proline Metabolism in Severely Burned Patients

Launched by MASSACHUSETTS GENERAL HOSPITAL · Sep 19, 2005

Trial Information

Current as of August 19, 2025

Withdrawn

Keywords

Parenteral Nutrition Burn Injury Stable Isotopes Proline Metabolic Kinetics Ornithine Metabolic Kinetics Glutamate Metabolic Kinetics Glutamine Metabolic Kinetics

ClinConnect Summary

Proline is a nutritionally dispensable (non-essential) amino acid. Its synthesis and catabolism is via the pathway of ornithine and glutamate. The latter two amino acids serve as immediate precursors for proline, as well as metabolites. Ornithine is one of the intermediates for urea cycle. Glutamate is metabolically connected to tricarboxylic acid (TCA) cycle, the major cycle for energy production.

It is hypothesized that the significantly increased rates of net nitrogen loss and energy "production", as the consequence of the accelerated activities of both the urea and TCA cycles in burn i...

Gender

ALL

Eligibility criteria

  • Inclusion Criteria:
  • Burn patients being treated at MGH Burn Unit with one or more of the following criteria: 1) \>=5% TBSA; 2) inhalation injury; or 3) resting energy expenditure (REE) of \>15% of the predicted Basal Metabolic Rate using the Harris-Benedict equation.
  • Must be receiving total parenteral nutrition in the course of their treatment.
  • Exclusion Criteria:
  • Patients with thyroid disease. Patients who are not hemodynamically stable or show unstable vital signs Patients at the stage of major organ failure, e.g. renal and/or liver failure.

About Massachusetts General Hospital

Massachusetts General Hospital (MGH) is a leading academic medical center located in Boston, Massachusetts, renowned for its commitment to advancing medical research and patient care. As a prominent teaching hospital affiliated with Harvard Medical School, MGH plays a pivotal role in clinical trials across a wide range of disciplines, including cardiology, oncology, neurology, and more. The institution is dedicated to fostering innovative research that translates into effective therapies and improved health outcomes. MGH's Clinical Trials Office provides comprehensive support to facilitate the design, implementation, and management of clinical studies, ensuring adherence to the highest ethical standards and regulatory compliance. With a focus on collaboration and patient-centered care, MGH strives to enhance medical knowledge and contribute to the future of healthcare.

Locations

Boston, Massachusetts, United States

Patients applied

0 patients applied

Trial Officials

Ronald G Tompkins, MD, ScD

Principal Investigator

MGH, Shriners Burn Hospital - Boston

Timeline

First submit

Trial launched

Trial updated

Estimated completion

Not reported

Similar Trials